China Pharma Experts Urge Regulations, Hospital Reforms In GSK Wake
This article was originally published in PharmAsia News
Executive Summary
The steady drip of revelations of alleged bribery behavior at GlaxoSmithKline in China has resulted in calls for new legislation and reforms at the nation's public hospitals.